FIMECS Inc
http://www.fimecs.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From FIMECS Inc
R&D Reorg Helps Astellas Move Swiftly With Protein Degraders
In selecting targeted protein degradation as a new Primary Focus area within its R&D effort, Astellas has moved rapidly to develop a potential first-in-class KRAS G12D degrader candidate ASP3082, helped by a reorganization last year to develop a more agile research function. The Japanese firm sees very broad potential for TPDs beyond oncology in the longer term.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice